Medical note: This article is for general education and is not a substitute for personalized medical care. Blood sugar goals and diabetes medications should be adjusted with a qualified health care professional, especially when insulin or medicines that can cause hypoglycemia are involved.
For decades, type 2 diabetes management often sounded like a game show with one rule: get the blood sugar number as low as possible. The lower the A1C, the bigger the imaginary trophy.
Modern diabetes guidelines are changing that conversation. They still emphasize the importance of preventing prolonged high blood sugar, but they increasingly recognize that aggressively chasing a very low A1C can create its own problems. For some people, especially older adults or those at high risk of hypoglycemia, a slightly higher target may be safer and more realistic.
That does not mean doctors suddenly think high blood sugar is harmless. It means the goal is no longer simply “lower.” The goal is better: better health, fewer complications, fewer dangerous lows, and a treatment plan that a person can actually live with.
What do the newer blood sugar guidelines actually say?
The headline can be confusing because different medical organizations recommend somewhat different A1C ranges. Current guidance does not establish one newly lowered number for every adult with type 2 diabetes. Instead, it places greater emphasis on individualized glycemic targets.
The American Diabetes Association’s 2026 Standards of Care continue to identify an A1C below 7% as appropriate for many nonpregnant adults, provided that the target can be reached without severe hypoglycemia or unacceptable effects on health and quality of life. A lower target, such as below 6.5%, may be reasonable for people in good health who have a low risk of treatment-related harm. Less stringent goals may be appropriate when frailty, cognitive limitations, serious medical conditions, or treatment risks outweigh the expected benefits.
The American College of Physicians takes a more moderate position. Its guidance recommends aiming for an A1C between 7% and 8% in most adults with type 2 diabetes and considering medication deintensification when A1C falls below 6.5%.
The Department of Veterans Affairs and Department of Defense also use target ranges rather than a universal cutoff. Their guidance includes ranges around 6% to 7% for selected healthier adults and progressively higher ranges for people with established complications, significant comorbidities, or limited life expectancy.
A simplified comparison of common A1C goals
| Patient situation | Possible A1C goal | Main consideration |
|---|---|---|
| Many nonpregnant adults | Below 7% | Balances long-term protection with treatment safety |
| Healthy adult with low hypoglycemia risk | Below 6.5% may be considered | Tighter control may offer additional benefit when safely achieved |
| Most adults under ACP guidance | 7% to 8% | Reduces pressure to pursue intensive medication-based control |
| Older adult with complex health problems | Often below 8% or an individualized range | Avoiding hypoglycemia and treatment burden becomes more important |
| Severe frailty or limited life expectancy | Symptom-based management may take priority | Comfort and prevention of acute symptoms may matter more than a specific A1C |
These are broad examples, not prescriptions. Two people with the same A1C can need completely different treatment plans.
What A1C measuresand what it misses
The A1C test estimates average blood glucose during roughly the previous two to three months. Glucose attaches to hemoglobin inside red blood cells, and the test reports the percentage of hemoglobin carrying attached glucose. A higher percentage generally indicates a higher average glucose level.
For diagnostic purposes, an A1C below 5.7% is considered normal, 5.7% to 6.4% falls within the prediabetes range, and 6.5% or higher may indicate diabetes when the result is properly confirmed. Those diagnostic cutoffs are not the same as treatment targets. A person who already has diabetes does not need to force an A1C into the nondiabetic range to prove they are doing a good job.
| A1C | Approximate estimated average glucose |
|---|---|
| 6% | 126 mg/dL |
| 7% | 154 mg/dL |
| 8% | 183 mg/dL |
| 9% | 212 mg/dL |
A1C is useful, but it is not a tiny all-knowing wizard. It does not show whether someone spent part of the month at dangerously low levels and another part at very high levels. Those extremes can average into a respectable-looking result.
Pregnancy, anemia, recent blood loss, blood transfusions, kidney problems, altered red blood cell turnover, and certain hemoglobin variants can also make A1C results less reliable. When an A1C result does not match home glucose readings or symptoms, clinicians may investigate further rather than immediately adding another prescription.
Why “lower is always better” became controversial
Long-term high blood sugar can damage blood vessels and contribute to eye disease, kidney disease, nerve damage, cardiovascular problems, and other complications. Improving glycemic control, particularly early in the course of type 2 diabetes, can reduce the risk of important microvascular complications.
However, large clinical trials showed that pushing blood sugar toward near-normal levels in people with long-standing type 2 diabetes and substantial cardiovascular risk does not automatically produce better outcomes.
In the ACCORD trial, an intensive treatment strategy targeting an A1C below 6% was stopped early because the intensive-treatment group experienced increased mortality. The study involved people with type 2 diabetes who already had cardiovascular disease or major cardiovascular risk factors, so its results should not be casually applied to every newly diagnosed patient. Still, it demonstrated that aggressive glucose lowering can have unintended consequences.
The ADVANCE and Veterans Affairs Diabetes Trial also found that intensive control did not deliver a sweeping reduction in major cardiovascular outcomes for people with more advanced type 2 diabetes, although certain microvascular benefits were observed. Meanwhile, long-term follow-up of earlier treatment studies suggests that good control established near diagnosis may provide lasting benefits.
The practical lesson is not that glucose control does not matter. It is that the timing, method, speed, medication burden, and characteristics of the individual matter enormously.
The hidden danger of overly aggressive control
Hypoglycemia generally refers to blood glucose below 70 mg/dL, although an individual’s alert level may differ. Symptoms can include shaking, sweating, hunger, dizziness, confusion, irritability, blurred vision, or an irregular heartbeat. Severe hypoglycemia can cause seizures, unconsciousness, coma, or death.
The risk is particularly relevant for people using insulin, sulfonylureas, or meglitinides. It may also rise when someone skips meals, exercises more than usual, drinks alcohol without eating, becomes ill, or develops reduced kidney function.
Older adults can be especially vulnerable. A low glucose episode may contribute to a fall, fracture, driving accident, hospitalization, or sudden loss of independence. Someone who lives alone may not have another person available to recognize confusion or administer glucagon.
This is why an A1C of 6.2% is not automatically “better” than 7.2%. If the lower number comes with repeated nighttime alarms, dizziness, emergency snacks, falls, or constant fear, the treatment plan may be too aggressive.
Who might benefit from a lower A1C target?
A target below 7%, and occasionally below 6.5%, may be considered for someone who:
- Was diagnosed relatively recently
- Has a long life expectancy
- Has few major diabetes complications
- Can reach the target without frequent hypoglycemia
- Uses treatments with a low risk of causing dangerous lows
- Feels comfortable with the monitoring and medication routine
- Wants tighter control after discussing its benefits and burdens
For example, a healthy 42-year-old whose A1C falls from 8.5% to 6.6% through sustainable nutrition changes, physical activity, weight management, and low-hypoglycemia-risk medication may be doing very well. There is no reason to raise the number simply because another guideline offers a broader range.
Who may need a less stringent goal?
A higher or wider target may be safer for someone with:
- Repeated or severe hypoglycemia
- Hypoglycemia unawareness
- Advanced kidney, heart, or liver disease
- Frailty, dementia, or major functional limitations
- A history of falls
- Multiple medications and a complicated dosing schedule
- Limited access to nutritious food, testing supplies, or medical care
- A shortened life expectancy
- Severe diabetes distress or an unsustainable treatment burden
ADA guidance for older adults specifically supports simplifying or deintensifying treatment when the plan causes excessive burden or creates more risk than benefit. At the end of life, avoiding hypoglycemia and symptomatic hyperglycemia may be more appropriate than chasing a laboratory target.
Deintensification does not mean abandoning treatment. It may mean reducing an insulin dose, replacing a medication that frequently causes lows, eliminating unnecessary finger sticks, or choosing a less demanding regimen. Medication changes should always be supervised.
Blood sugar management is now about more than A1C
Modern type 2 diabetes care considers cardiovascular health, kidney protection, body weight, liver health, hypoglycemia risk, cost, and quality of life alongside glucose levels.
For people with heart failure, chronic kidney disease, obesity, or elevated cardiovascular risk, clinicians may recommend an SGLT2 inhibitor, GLP-1 receptor agonist, or related therapy for benefits that extend beyond A1C reduction. Current ADA recommendations support using certain medications for heart and kidney protection regardless of a person’s starting A1C.
This represents an important shift. A medication is no longer judged solely by how dramatically it lowers the glucose number. The better question is what it does for the whole person.
Continuous glucose monitoring adds another layer
Continuous glucose monitors can reveal patterns that an A1C cannot. Common CGM goals for many adults include spending more than 70% of the day between 70 and 180 mg/dL, less than 4% below 70 mg/dL, and less than 1% below 54 mg/dL. These targets must also be individualized.
A person with an A1C of 6.8% and almost no hypoglycemia may have a healthier glucose profile than someone with an A1C of 6.4% who repeatedly falls below 54 mg/dL. Averages can be polite little liars when variability is ignored.
What should someone with type 2 diabetes do now?
Do not stop insulin, skip pills, or deliberately raise blood sugar because of a headline. Guideline changes are meant to improve shared decision-making, not inspire medication roulette.
At the next appointment, useful questions include:
- What is my personal A1C target, and why?
- Am I experiencing more hypoglycemia than I realize?
- Do my home readings or CGM data match my A1C?
- Could any of my medications be simplified?
- Would a different medicine offer heart or kidney protection?
- How often should my A1C be checked?
- Which symptoms or readings require an urgent call?
For many adults, typical daily glucose targets remain 80 to 130 mg/dL before meals and below 180 mg/dL one to two hours after starting a meal. Personal targets may differ because of age, health conditions, pregnancy, medication use, and hypoglycemia risk.
A1C is commonly checked every three months when treatment has changed or goals are not being met. People with stable readings who are meeting their goals may need testing about every six months.
Experiences behind personalized blood sugar targets
The following examples are composite educational scenarios. They illustrate common experiences but do not describe specific identifiable patients or provide individual medical advice.
The newly diagnosed patient who wants a “perfect” score
Imagine a 47-year-old office manager named Daniel who receives an A1C result of 8.6%. He immediately treats diabetes like an emergency homework assignment. He removes nearly every carbohydrate from the kitchen, checks his glucose obsessively, exercises after every meal, and feels personally insulted whenever his meter displays a three-digit number.
After several months, his A1C reaches 6.5%. That improvement is meaningful, but Daniel is exhausted. He avoids family dinners, worries about every apple, and interprets normal fluctuations as failure.
His care team helps him replace perfectionism with a sustainable plan. He continues taking prescribed medication, adds fiber-rich carbohydrates back into meals, follows a manageable activity routine, and checks glucose at times that provide useful information. His A1C later settles around 6.7%, with fewer spikes and much less anxiety.
The lesson is not that 6.5% was too low. It is that a good number achieved through misery may not be a durable victory. Diabetes management needs to survive birthdays, vacations, stressful workweeks, and the occasional restaurant menu written entirely in butter.
The older adult whose excellent A1C hides dangerous lows
Now consider Maria, age 76, who has used insulin for many years. Her A1C is 6.1%, and relatives congratulate her on “beating diabetes.” What the laboratory result does not reveal is that she sometimes wakes sweaty and confused. She has also stumbled twice while walking to the bathroom at night.
A review of her glucose readings shows repeated overnight hypoglycemia. Her clinician simplifies the insulin schedule, adjusts the dose, and sets a less aggressive A1C goal. Several months later, Maria’s A1C is 7.3%, but the nighttime lows have largely disappeared.
On paper, her A1C increased. In real life, she sleeps better, feels steadier, and is less likely to fall. That is not failed diabetes care. It is successful risk reduction.
The patient whose treatment changes even though A1C looks acceptable
Finally, picture Andre, age 61, whose A1C is 7.2%. He assumes his appointment will focus entirely on lowering it below 7%. Instead, testing shows early chronic kidney disease, and his clinician discusses a medication with demonstrated kidney and cardiovascular benefits.
The treatment decision is not based solely on whether the new medicine will shave a few tenths of a percentage point from his A1C. It reflects a broader goal: protecting organs and reducing long-term risk.
Andre also learns that blood pressure management, cholesterol treatment, smoking status, sleep, nutrition, physical activity, and kidney monitoring are part of diabetes care. His glucose still matters, but it is no longer the only character in the story demanding a speaking role.
The common thread
These experiences demonstrate why personalized targets matter. The same A1C can represent smooth, safe glucose control in one person and frequent dangerous lows in another. A slightly higher number can sometimes reflect a healthier treatment plan, while a lower number may be entirely appropriate when it is achieved safely and sustainably.
The most useful target is not necessarily the lowest number a person can force onto a lab report. It is the range that provides meaningful long-term protection without creating excessive short-term harm or turning daily life into a nonstop medical obstacle course.
Conclusion
Newer type 2 diabetes guidelines have not declared that everyone should aim for the same lower blood sugar level. Instead, they have lowered the pressure to pursue aggressive control at any cost.
An A1C below 7% remains appropriate for many adults. Some healthy people may safely pursue a lower goal, while others may benefit from a target closer to 7% to 8% or a wider individualized range. Age, diabetes duration, medication type, cardiovascular and kidney health, hypoglycemia history, life expectancy, personal preferences, and treatment burden all influence the decision.
The central message is refreshingly human: treat the person, not just the percentage. A successful diabetes plan should protect future health while remaining safe enough, affordable enough, and realistic enough to follow today.
